These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16843092)

  • 1. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Goldsmith SR
    Am J Med; 2006 Jul; 119(7 Suppl 1):S93-6. PubMed ID: 16843092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
    Goldsmith SR
    Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH; Serrano C
    Int J Cardiol; 2007 Aug; 120(1):1-9. PubMed ID: 17346825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy.
    Schrier RW; Fassett RG; Ohara M; Martin PY
    Proc Assoc Am Physicians; 1998; 110(5):407-11. PubMed ID: 9756091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
    Schwarz ER; Sanghi P
    Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin antagonism in heart failure.
    Goldsmith SR; Gheorghiade M
    J Am Coll Cardiol; 2005 Nov; 46(10):1785-91. PubMed ID: 16286160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G; Klapholz M
    Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin-receptor antagonists.
    Hoorn EJ; Zietse R
    Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin antagonists in the management of heart failure.
    Rossi J; Orlandi C; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):323-30. PubMed ID: 17338675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P
    Arch Mal Coeur Vaiss; 2006 Mar; 99(3):215-20. PubMed ID: 16618024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
    J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.
    Streefkerk JO; van Zwieten PA
    Auton Autacoid Pharmacol; 2006 Apr; 26(2):141-8. PubMed ID: 16553642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure.
    Goldsmith SR
    Cleve Clin J Med; 2006 Jun; 73 Suppl 2():S20-3; discussion S30-3. PubMed ID: 16786909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene.
    Mayinger B; Hensen J
    Exp Clin Endocrinol Diabetes; 1999; 107(3):157-65. PubMed ID: 10376439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin antagonism: a future treatment option in heart failure.
    Sanghi P; Uretsky BF; Schwarz ER
    Eur Heart J; 2005 Mar; 26(6):538-43. PubMed ID: 15695526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.